Publication date: Sep 26, 2025 Mycobacterium abscessus (MAB), a rapidly growing non-tuberculous mycobacterium, is becoming increasingly recognized as a significant pathogen affecting humans. These bacteria particularly impact individuals with cystic ... Read more

Publication date: Sep 04, 2025 Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for ... Read more

Publication date: Nov 19, 2025 The rise of drug-resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ-587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical ... Read more

Publication date: Oct 30, 2025 This review examines the potential of nanosystems for targeted tuberculosis (TB) therapy, focusing on biodegradable polymeric, lipid-based, extracellular vesicles, and selected inorganic nanocarriers engineered to ... Read more

Publication date: Jul 17, 2025 Mycobacterium tuberculosis-an acid-fast staining bacterium-is a serious global health challenge that can have both short-term and long-term complications. Although the immune response helps trap the ... Read more

Publication date: Jul 20, 2025 About a quarter of the world’s population is infected with Mycobacterium tuberculosis. Growing antibiotic resistance by this microorganism is a major problem in the therapy ... Read more

Publication date: Jul 30, 2025 Establishing efficacy benchmarks in preclinical tuberculosis (TB) models is essential for optimizing and prioritizing therapeutic regimens. However, standardized classification methods for comparing high-performing regimens are ... Read more